FIELMANN AG (ADR/1/5)O.N. Net Assets
FIELMANN AG (ADR/1/5)O.N. net assets. Based on the latest financial reports, FIELMANN AG (ADR/1/5)O.N. (FIE1) has net assets worth €972.00 Million EUR (≈ $1.14 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.39 Billion ≈ $2.79 Billion USD) and total liabilities (€1.42 Billion ≈ $1.66 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See net asset quality index of FIELMANN AG (ADR/1/5)O.N. to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €972.00 Million |
| % of Total Assets | 40.71% |
| Annual Growth Rate | 1.52% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.15 |
Net Assets of FIELMANN AG (ADR/1/5)O.N. (2021–2024)
Net assets of FIELMANN AG (ADR/1/5)O.N. from 2021 to 2024. This chart illustrates how FIELMANN AG (ADR/1/5)O.N.'s net assets have evolved over time, based on quarterly financial data. Also explore FIELMANN AG (ADR/1/5)O.N. (FIE1) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Net Assets for FIELMANN AG (ADR/1/5)O.N. (2021–2024)
The table below shows the annual net assets of FIELMANN AG (ADR/1/5)O.N. from 2021 to 2024. For live market cap and overall valuation, see how much is FIELMANN AG (ADR/1/5)O.N. worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €913.14 Million ≈ $1.07 Billion |
+7.36% |
| 2023-12-31 | €850.53 Million ≈ $994.36 Million |
-0.32% |
| 2022-12-31 | €853.26 Million ≈ $997.55 Million |
-2.24% |
| 2021-12-31 | €872.79 Million ≈ $1.02 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to FIELMANN AG (ADR/1/5)O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 68104800000.0% over the analyzed period, indicating profitable operations and earnings retention.
FIELMANN AG (ADR/1/5)O.N. Net Assets Breakdown (December 2024)
FIELMANN AG (ADR/1/5)O.N. net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €681.05 Million | 75.75% |
| Other Components | €218.08 Million | 24.25% |
| Total Equity | €899.13 Million | 100.00% |
FIELMANN AG (ADR/1/5)O.N. Competitors by Market Cap
The table below lists competitors of FIELMANN AG (ADR/1/5)O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Alm. Brand
CO:ALMB
|
$3.84 Billion |
|
KINGDEE INT. UNS.ADR/100
F:KDID
|
$3.84 Billion |
|
Auras Technology Co Ltd
TWO:3324
|
$3.84 Billion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
$3.84 Billion |
|
Andon Health Co Ltd
SHE:002432
|
$3.83 Billion |
|
Dorman Products Inc
NASDAQ:DORM
|
$3.83 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
$3.83 Billion |
|
Predictive Discovery Ltd
AU:PDI
|
$3.83 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in FIELMANN AG (ADR/1/5)O.N.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 792,025,000 to 899,131,000, a change of 107,106,000 (13.5%).
- Net income of 152,108,000 contributed positively to equity growth.
- Dividend payments of 83,971,000 reduced retained earnings.
- Other factors increased equity by 38,969,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €152.11 Million | +16.92% |
| Dividends Paid | €83.97 Million | -9.34% |
| Other Changes | €38.97 Million | +4.33% |
| Total Change | €- | 13.52% |
Book Value vs Market Value Analysis
This analysis compares FIELMANN AG (ADR/1/5)O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.84x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €9.76 | €8.95 | x |
| 2022-12-31 | €9.54 | €8.95 | x |
| 2023-12-31 | €9.43 | €8.95 | x |
| 2024-12-31 | €10.70 | €8.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently FIELMANN AG (ADR/1/5)O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.92%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.72%
- • Asset Turnover: 0.96x
- • Equity Multiplier: 2.63x
- Recent ROE (16.92%) is above the historical average (15.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 16.69% | 8.16% | 0.97x | 2.12x | €54.87 Million |
| 2022 | 12.94% | 5.89% | 1.00x | 2.21x | €23.54 Million |
| 2023 | 15.76% | 6.33% | 0.98x | 2.55x | €45.58 Million |
| 2024 | 16.92% | 6.72% | 0.96x | 2.63x | €62.19 Million |
Industry Comparison
This section compares FIELMANN AG (ADR/1/5)O.N.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $5,548,175,105
- Average return on equity (ROE) among peers: -88.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| FIELMANN AG (ADR/1/5)O.N. (FIE1) | €972.00 Million | 16.69% | 1.46x | $3.83 Billion |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $709.04 Million | 17.68% | 0.69x | $2.39 Billion |
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | $4.02 Billion | 4.35% | 1.05x | $17.02 Billion |
| MEDIMI AB AK (79T) | $332.69K | -959.52% | 4.12x | $1.70 Million |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-736.70K | 0.00% | 0.00x | $210.67K |
| STEVANATO GROUP SPA O.N. (87N) | $1.13 Billion | 12.86% | 0.83x | $1.05 Billion |
| Carl Zeiss Meditec AG (AFX) | $1.24 Billion | 10.83% | 0.31x | $2.23 Billion |
| CARL ZEISS MEDITEC ADR 1 (AFXA) | $2.06 Billion | 8.69% | 0.65x | $2.14 Billion |
| Bio-gate AG (BIG1) | $3.45 Million | -46.99% | 0.52x | $7.12 Million |
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | $8.17 Billion | 59.07% | 0.94x | $12.73 Billion |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $38.15 Billion | 5.64% | 0.59x | $67.43 Billion |
About FIELMANN AG (ADR/1/5)O.N.
Fielmann Group AG engages in vision care and audiology business in Germany, Switzerland, Austria, Spain, North America, and internationally. The company manufactures and sells visual aids mainly glasses, eyewear frames and lenses, sunglasses, contact lenses, accessories, hearing systems and its accessories, as well as personal protective equipment. It offers its products under the fielmann, Optik… Read more